The molecular signature of Hsp90 inhibition represents a fundamental pharmacodynamic biomarker of efficacy in cancer cell lines, and has been well validated in human tumor xenografts as well as to measure target inhibition in cancer patients receiving treatments with selective Hsp90 inhibitors (30–32). The gene discussed is HSP90AA1; the disease is cancer.